Protective effect of abamectin on acute lung injury induced by lipopolysaccharide in mice

Fundamental and Clinical Pharmacology

Volumn 25, Issue 6, 2011, Pages 700-707

  Zhang, Xiaozhe ^a   Li, Jianhua ^a   Chen, Chi ^a   Ci, Xinxin ^a   Yu, Qinlei ^a   Zhang, Xichen ^a   Deng, Xuming ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Abamectin; Acute lung injury; Cytokine; Lipopolysaccharide

Indexed keywords

ABAMECTIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MYELOPEROXIDASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; LUNG LAVAGE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ACUTE LUNG INJURY; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INTERLEUKIN-6; IVERMECTIN; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; NEUTROPHILS; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054954583     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00896.x     Document Type: Article

References (33)

1. Čulić O., Eraković V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. (2001) 429 209-229.
2. Leclercq R., Courvalin P. Resistance to macrolides and related antibioticsin Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2002) 46 2727-2734.
3. Bermejo-Martin J.F., Kelvin D.J., Eiros J.M., Castrodeza J., Ortiz de Lejarazu R. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J. Infect. Dev. Ctries. (2009) 3 159-161.
4. Ianaro A., Ialenti A., Maffia P. et al. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. (2000) 292 156-163.
5. Labro M.T. Anti-inflammatory activity of macrolides: a new therapeutic potential. J. Antimicrob. Chemother. (1998) 41 37-46.
6. Sato K., Suga M., Akaike T. et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am. J. Respir. Crit. Care Med. (1998) 157 853-857.
7. Giamarellos-Bourboulis E.J., Adamis T., Laoutaris G. et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2004) 48 93-99.
8. Burg R.W., Miller B.M., Baker E.E. et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob. Agents Chemother. (1979) 15 361-367.
9. Lofgren C.S., Williams D.F. Avermectin B1a: highly potent inhibitor of reproduction by queens of the red imported fire ant (Hymenoptera: Formicidae). J. Econ. Entomol. (1982) 75 798-803.
10. Rohrer S.P., Jacobson E.B., Hayes E.C., Birzin E.T., Schaeffer J.M. Immunoaffinity purification of avermectin-binding proteins from the free-living nematode Caenorhabditis elegans and the fruitfly Drosophila melanogaster. Biochem. J. (1994) 302 339-345.
11. Ci X.X., Li H.Y., Yu Q.L. et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam. Clin. Pharmacol. (2009) 23 449-455.
12. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N. Engl. J. Med. (2000) 342 1334-1349.
13. Bhatia M., Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Pathol. (2004) 202 145-156.
14. Lee W.L., Downey G.P. Neutrophil activation and acute lung injury. Curr. Opin. Crit. Care. (2001) 7 1-7.
15. Mayeux P.R. Pathobiology of lipopolysaccharide. J. Toxicol. Environ. Health (1997) 51 415-435.
16. Delgado A.V., McManus A.T., Chambers J.P. Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides (2003) 37 355-361.
17. Ahmed S., Anuntiyo J., Malemud C.J., Haqqi T.M. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid. Based. Complement. Alternat. Med. (2005) 2 301-308.
18. El-Kebir D., Jozsef L., Pan W., Filep J.G. Myeloperoxidase delays neutrophil apoptosis through CD11b/CD18 integrins and prolongs inflammation. Circ. Res. (2008) 103 352-359.
19. Xie Y.C., Dong X.W., Wu X.M., Yan X.F., Xie Q.M. Inhibitory effects of flavonoids extracted from licorice on lipopolysaccharide-induced acute pulmonary inflammation in mice. Int. Immunopharmacol. (2009) 9 194-200.
20. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124 783-801.
21. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science (2003) 300 1524-1525.
22. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE (2003) 171 re3.
23. Szarka R.J., Wang N., Gordon L., Nation P.N., Smith R.H. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. J. Immunol. Methods (1997) 202 49-57.
24. Faffe D.S., Siedl V.R., Chagas P.S. et al. Respiratory effects of lipopolysaccharide-induced inflammatory lung injury in mice. Eur. Respir. J. (2000) 15 85-91.
25. Miller S.I., Ernst R.K., Bader M.W. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. (2005) 3 36-46.
26. Matthay M.A., Zimmerman G.A. Acute lung injury and the acute respiratory distresssyndrome: four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol. (2005) 33 319-327.
27. Sibille Y., Reynold H.Y. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am. Rev. Respir. Dis. (1990) 141 471-501.
28. Minamino T., Komuro I. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. J. Clin. Invest. (2006) 116, 2316-2319.
29. Yin H., Jin X.B., Gong Q. et al. Fructose-1, 6-diphosphate attenuates acute lung injury induced by lipopolysaccharide in mice. Int. Immunopharmacol. (2008) 8 1842-1847.
30. Sone Y., Serikov V.B., Staub N.C. Sr. Intravascular macrophage depletion attenuates endotoxin lung injury in anesthetized sheep. J. Appl. Physiol. (1999) 87, 1354-1359.
31. Staub N.C. Sr, Longwortb K.E., Serikov V., Jerome E.H., Elsasser T. Detergent inhibits 70-90% of responses to intravenous endotoxin in awake sheep. J. Appl. Physiol. (2001) 90 1788-1797.
32. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-(kappa)B activity. Annu. Rev. Immunol. (2000) 18 621-663.
33. Kim E.K., Choi E.-J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta (2010) 1802, 396-405.